9.005
price up icon1.30%   0.105
 
loading
Schlusskurs vom Vortag:
$8.90
Offen:
$8.9
24-Stunden-Volumen:
1.96M
Relative Volume:
0.15
Marktkapitalisierung:
$10.57B
Einnahmen:
$14.33B
Nettoeinkommen (Verlust:
$-3.79B
KGV:
-2.8407
EPS:
-3.17
Netto-Cashflow:
$1.84B
1W Leistung:
+0.96%
1M Leistung:
+1.64%
6M Leistung:
-19.07%
1J Leistung:
-22.75%
1-Tages-Spanne:
Value
$8.895
$9.085
1-Wochen-Bereich:
Value
$8.835
$9.285
52-Wochen-Spanne:
Value
$6.85
$13.55

Viatris Inc Stock (VTRS) Company Profile

Name
Firmenname
Viatris Inc
Name
Telefon
(724) 514-1465
Name
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Name
Mitarbeiter
32,000
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
VTRS's Discussions on Twitter

Vergleichen Sie VTRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
9.005 10.73B 14.33B -3.79B 1.84B -3.17
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
149.09 69.30B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.51 47.50B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.585 44.47B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.16 18.83B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
296.61 13.43B 2.99B 1.21B 1.13B 25.06

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-06 Eingeleitet Goldman Neutral
2024-07-19 Fortgesetzt Jefferies Buy
2023-10-23 Herabstufung BofA Securities Neutral → Underperform
2023-06-23 Herabstufung Barclays Equal Weight → Underweight
2023-04-24 Herabstufung Barclays Overweight → Equal Weight
2023-02-17 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-01-27 Hochstufung Jefferies Hold → Buy
2022-11-10 Hochstufung UBS Sell → Neutral
2022-11-08 Hochstufung Piper Sandler Underweight → Neutral
2022-10-21 Fortgesetzt Jefferies Hold
2022-06-14 Eingeleitet UBS Sell
2022-05-10 Herabstufung Piper Sandler Neutral → Underweight
2022-03-01 Herabstufung BofA Securities Buy → Neutral
2022-03-01 Herabstufung Raymond James Outperform → Mkt Perform
2021-06-15 Eingeleitet Citigroup Neutral
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-03-08 Herabstufung Goldman Buy → Neutral
2021-03-02 Herabstufung JP Morgan Overweight → Neutral
2021-02-26 Herabstufung Wolfe Research Outperform → Peer Perform
2021-01-05 Eingeleitet Argus Hold
2020-12-14 Eingeleitet Bernstein Mkt Perform
Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

pulisher
09:23 AM

What analysts say about Viatris Inc. stockExplosive capital appreciation - jammulinksnews.com

09:23 AM
pulisher
08:39 AM

What drives Viatris Inc. stock priceFree Trend-Following Techniques - jammulinksnews.com

08:39 AM
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - TradingView

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is Viatris Inc. a good long term investmentGame-changing capital returns - PrintWeekIndia

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Why Is Viatris Stock Falling In Pre-market? - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye ointment fails late-stage study for eye condition, shares fall - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com Australia

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye therapy fails to meet late-stage trial goal - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN

Jul 18, 2025
pulisher
Jul 16, 2025

Hypopituitarism Treatment Market Expansion Supported - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

What makes Viatris Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Non-Opioid Patch Market CAGR 6.6 percent overview and leading - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Viatris Inc. (VTRS) Stock Analysis: Evaluating a 24.86% Potential Upside Amidst Financial Headwinds - DirectorsTalk Interviews

Jul 14, 2025
pulisher
Jul 09, 2025

J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug - Seeking Alpha

Jul 09, 2025
pulisher
Jul 08, 2025

When (VTRS) Moves Investors should Listen - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 08, 2025

Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN

Jul 08, 2025
pulisher
Jul 08, 2025

J&J defeats generic drugmakers in US appeal over schizophrenia treatment - TradingView

Jul 08, 2025
pulisher
Jul 08, 2025

J&J Invega Sustenna Patent Beats Teva, Viatris Appeals (Correct) - Bloomberg Law News

Jul 08, 2025
pulisher
Jul 07, 2025

Viatris Inc. (VTRS) Stock Analysis: Exploring a 22.18% Potential Upside Amidst Strong Free Cash Flow and High Dividend Yield - DirectorsTalk Interviews

Jul 07, 2025
pulisher
Jun 28, 2025

Theravance higher as China approves Viatris-partnered COPD therapy - MSN

Jun 28, 2025
pulisher
Jun 27, 2025

Viatris says second phase 3 trial of blurred vision drug meets goal - Seeking Alpha

Jun 27, 2025
pulisher
Jun 26, 2025

Breakthrough in Presbyopia Treatment: Viatris Phase 3 Trial Shows Powerful Vision Improvement Results - Stock Titan

Jun 26, 2025
pulisher
Jun 25, 2025

Is Viatris Stock Underperforming the S&P 500? - MSN

Jun 25, 2025

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_specialty_generic RDY
$14.38
price down icon 1.17%
$133.00
price up icon 0.51%
$297.05
price up icon 1.47%
$14.83
price up icon 0.99%
$71.41
price down icon 0.22%
Kapitalisierung:     |  Volumen (24h):